In this video, InMed Pharmaceuticals’ CEO Eric A. Adams speaks about the company’s therapeutic development of cannabinol (CBN), a rare cannabinoid showing potential to treat serious diseases with high unmet needs. InMed is the first company to advance CBN into clinical trials for therapeutic development. Mr. Adams also provides an update on the company’s programs in epidermolysis bullosa (EB) and glaucoma and its biosynthesis platform.
Current research into the potential therapeutic effects of cannabinol (CBN)
How do cannabinoids interact with the human body? There has been a significant growth in interest and research into the potential therapeutic properties of cannabinoids.
April 8, 2021
